title: Levalbuterol has not been established to have therapeutic advantage over racemic albuterol.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Asmus
authors.forename: Leslie
authors.initials: L
authors.lastname: Hendeles
authors.forename: Miles
authors.initials: M
authors.lastname: Weinberger
authors.forename: Richard C
authors.initials: RC
authors.lastname: Ahrens
authors.forename: Hans
authors.initials: H
authors.lastname: Bisgaard
authors.forename: Jan
authors.initials: J
authors.lastname: Lötvall
authors.forename: Paul M
authors.initials: PM
authors.lastname: O'Byrne
authors.forename: Donald W
authors.initials: DW
authors.lastname: Cockcroft
mesh_terms: D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000420:Albuterol / Q000627:therapeutic use*; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D002648:Child; D003257:Consumer Product Safety; D004305:Dose-Response Relationship, Drug; D005541:Forced Expiratory Volume; D006801:Humans
chemical_list: D000318:Adrenergic beta-Agonists; D018927:Anti-Asthmatic Agents; D000420:Albuterol